| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/14/2000 | WO2000053169A2 Method of inhibiting a chaperone protein |
| 09/14/2000 | WO2000053167A2 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| 09/14/2000 | WO2000037609A3 Orally immunogenic bacterial enterotoxins expressed in transgenic plants |
| 09/14/2000 | WO2000037110A3 Ribavirin-pegylated interferon alfa induction hcv combination therapy |
| 09/14/2000 | WO2000035480A3 Peptides useful in diagnosing and treating hiv-induced acquired immune deficiency disease |
| 09/14/2000 | WO2000035430A3 Homer a new target of treating psychiatric disorders |
| 09/14/2000 | WO2000035409A3 Hiv-i fusion inhibition compounds |
| 09/14/2000 | WO2000034496A3 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene |
| 09/14/2000 | WO2000031263A3 Gtpase associated proteins |
| 09/14/2000 | WO2000026395A3 Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors |
| 09/14/2000 | WO2000025818A8 asuE/trmU |
| 09/14/2000 | WO2000025812A3 Method for preparing solid phase conjugate vaccines |
| 09/14/2000 | WO1999066875A3 Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism |
| 09/14/2000 | DE19910159A1 Spezifische lgY-Eidotterantikörper, ihre Gewinnung und ihre Verwendung Specific IgY-egg yolk, their production and their use |
| 09/14/2000 | DE19910044A1 Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff Viral particles released after infection by human cytomegalovirus and their use as a vaccine |
| 09/14/2000 | CA2367315A1 Apoptosis inducing molecule ii and methods of use |
| 09/14/2000 | CA2367108A1 Method of inhibiting a chaperone protein |
| 09/14/2000 | CA2366689A1 Bifunctional molecules for delivery of therapeutics |
| 09/14/2000 | CA2366609A1 4-oxo-4,7-dihydro-thieno¬2,3-b|pyridine-5-carboxamides as antiviral agents |
| 09/14/2000 | CA2366607A1 Thiazolyl urea derivatives and their utilization as antiviral agents |
| 09/14/2000 | CA2365903A1 Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine |
| 09/14/2000 | CA2365813A1 Stable recombinant influenza viruses free of helper viruses |
| 09/14/2000 | CA2364500A1 Cyanovirin conjugates, matrix-anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use |
| 09/14/2000 | CA2364449A1 Anti-hiv agent |
| 09/14/2000 | CA2364442A1 Intranasal delivery of pneumococcal polysaccharide vaccines |
| 09/14/2000 | CA2364257A1 Liposome preparations |
| 09/14/2000 | CA2363593A1 Nucleic acid respiratory syncytial virus vaccines |
| 09/14/2000 | CA2363255A1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 09/14/2000 | CA2362422A1 Polynucleotides and proteins encoded thereby |
| 09/14/2000 | CA2361370A1 Prevention and treatment of viral infections |
| 09/13/2000 | EP1035209A1 Stable recombinant influenza viruses free of helper viruses |
| 09/13/2000 | EP1035203A1 Genetically engineered cell culture adapted infectious bursal diseases virus (IBDV) mutants |
| 09/13/2000 | EP1035133A2 Fusion proteins comprising carriers that can induce a dual immune response |
| 09/13/2000 | EP1034795A2 Conjugates of lipids and biologically active compounds |
| 09/13/2000 | EP1034792A1 Intranasal delivery of pneumococcal polysaccharide vaccines |
| 09/13/2000 | EP1034791A1 Anti-hypoxic and anti-ischemic drug |
| 09/13/2000 | EP1034790A2 HIV therapy |
| 09/13/2000 | EP1034785A2 Hepatitis C virus diagnostics and vaccines |
| 09/13/2000 | EP1034784A2 Pharmaceutical formulations containing clavulanic acid and an antibacterial agent |
| 09/13/2000 | EP1034295A1 ribA |
| 09/13/2000 | EP1034289A1 Alphavirus vectors for paramyxovirus vaccines |
| 09/13/2000 | EP1034277A2 EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS) |
| 09/13/2000 | EP1034276A1 Novel era |
| 09/13/2000 | EP1034252A2 Attenuated strains of mycobacteria |
| 09/13/2000 | EP1034185A2 Pharmaceutical compositions containing the long pentraxin ptx3 |
| 09/13/2000 | EP1034182A1 Inhibition of nuclear import by backbone cyclic peptide analogs |
| 09/13/2000 | EP1034175A1 Substituted phenyloxazolidinones and their use as antibiotics |
| 09/13/2000 | EP1034173A2 Method for producing 8-methoxy-quinoline carboxylic acids |
| 09/13/2000 | EP1034167A1 Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors |
| 09/13/2000 | EP1034004A1 Recombinant mycoplasma hyopneumoniae vaccine |
| 09/13/2000 | EP1034000A1 Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection |
| 09/13/2000 | EP1033992A1 Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
| 09/13/2000 | EP1033969A1 Compositions adapted for prolonged residence in the nasal pharynx |
| 09/13/2000 | EP0817787A4 Nitrogenous macrocyclic compounds |
| 09/13/2000 | EP0764166B1 Corticotropin releasing factor antagonists |
| 09/13/2000 | EP0763017B1 N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors |
| 09/13/2000 | EP0652776B1 Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them |
| 09/13/2000 | EP0607193B1 Triazole antifungal agents |
| 09/13/2000 | CN1266459A Method and reagents for vaccination which generate a CD8 T cell immune response |
| 09/13/2000 | CN1266456A Kinase activating dependent cyclin protein kinases, and their uses |
| 09/13/2000 | CN1266423A 1-amino-alkylcyclohexane NMDA receptor antagonists |
| 09/13/2000 | CN1265919A Method for production of medicine for treating beriberi |
| 09/13/2000 | CN1265895A Specific medicine for treating common cold |
| 09/13/2000 | CN1056383C Chinese trichosanthes protein, preparation method and use in pharmacy |
| 09/13/2000 | CN1056301C Oral liquid for treating appendicitis |
| 09/13/2000 | CN1056291C Traditional Chinese medicine for treating scorofula |
| 09/13/2000 | CN1056289C Antiphthitic medicine |
| 09/12/2000 | USRE36866 Anti-aids immunotoxins |
| 09/12/2000 | US6117903 Extracts of Salvia species having antiviral activity |
| 09/12/2000 | US6117894 Maintains its stability after six months or more of storage. |
| 09/12/2000 | US6117887 Inhibition of 26S and 20S proteasome by indanones |
| 09/12/2000 | US6117868 Treatment of gastrointestinal ulcers or gastritis caused by microbial infection |
| 09/12/2000 | US6117857 Pharmaceutical composition |
| 09/12/2000 | US6117849 S-(+)-adenosylmethionine and 3'-azido-2', 3'-dideoxy-nucleoside complexes as potent inhibitors of HIV-replication |
| 09/12/2000 | US6117667 Method for producing an adapted virus population from an African green monkey kidney cell line |
| 09/12/2000 | US6117662 Respiratory nitrate reductase alpha subunit |
| 09/12/2000 | US6117653 Hepatitis B surface antigen vaccine |
| 09/12/2000 | US6117640 Recombinant vaccine made in E. coli against dengue virus |
| 09/12/2000 | US6117427 Administering immunogenic protein-alkaloid conjugate having indolo(4,3-fg)quinoline derivative |
| 09/12/2000 | US6117412 Administering bismuth compound containing additional heavy atom as contrast enhancer; x-rays, magnetic resonance, ultrasound, and scintigraphic imaging |
| 09/12/2000 | CA2159817C Pyrimidine acyclonucleoside derivatives |
| 09/12/2000 | CA2158024C A mycoplasma gallisepticum antigen, dna encoding the antigen, recombinant vector bearing the dna and recombinant virus utilizing the recombinant vector as well as use thereof |
| 09/08/2000 | WO2000052185A1 Application of dna vectors for the treatment of viral infection |
| 09/08/2000 | WO2000052145A2 Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| 09/08/2000 | WO2000052134A2 Inhibitors of prenyl-protein transferase |
| 09/08/2000 | WO2000052055A1 SPECIFIC EGG YOLK ANTIBODIES IgY, THE OBTAINMENT AND USE THEREOF |
| 09/08/2000 | WO2000052053A1 Antibodies against phosphomannan that are protective against candidiasis |
| 09/08/2000 | WO2000052040A1 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| 09/08/2000 | WO2000052037A1 Echinocandin/carbohydrate complexes |
| 09/08/2000 | WO2000052028A1 TUMOR NECROSIS FACTOR RECEPTORS 6α and 6$g(b) |
| 09/08/2000 | WO2000052010A1 Crystal modification d of 8-cyano-1-cyclopropyl-7- (1s, 6s- 2,8- diazabicyclo- [4.3.0] nonan-8-yl) -6-fluoro -1,4-dihydro -4-oxo -3-quinoline carboxylic acid |
| 09/08/2000 | WO2000052009A1 Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8- diazabicyclo -[4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic |
| 09/08/2000 | WO2000051645A1 Polymer compositions for polynucleotide delivery |
| 09/08/2000 | WO2000051641A1 Pharmaceutical combination of antiviral agents |
| 09/08/2000 | WO2000051636A1 Modulators of fgl2 prothrombinase |
| 09/08/2000 | WO2000051634A1 Vaccine preparations containing fatty acids as constituent |
| 09/08/2000 | WO2000051633A2 MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY $i(HAEMOPHILUS INFLUENZAE) |
| 09/08/2000 | WO2000051631A2 Pegylated alpha interferon for hiv therapy |
| 09/08/2000 | WO2000051625A1 Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses |
| 09/08/2000 | WO2000051614A1 Inhibitors of prenyl-protein transferases |